Focus
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Focus 5:368-380, Summer 2007
© 2007 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Foa, E. B.
* Articles by Tu, X.
* Search for Related Content
PubMed
* Articles by Foa, E. B.
* Articles by Tu, X.
Related Collections
*Related Article

INFLUENTIAL PUBLICATIONS

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder

Edna B. Foa, Ph.D., Michael R. Liebowitz, M.D., Michael J. Kozak, Ph.D., Sharon Davies, R.N., Rafael Campeas, M.D., Martin E. Franklin, Ph.D., Jonathan D. Huppert, Ph.D., Kevin Kjernisted, M.D., Vivienne Rowan, Ph.D., Andrew B. Schmidt, C.S.W., H. Blair Simpson, M.D., Ph.D., and Xin Tu, Ph.D.

Objective:The purpose of the study was to test the relative and combined efficacy of clomipramine and exposure and ritual prevention in the treatment of obsessive-compulsive disorder (OCD) in adults. Serotonin reuptake inhibitors (SRIs) and cognitive behavior therapy by exposure and ritual prevention are both established treatments for OCD, yet their relative and combined efficacy have not been demonstrated conclusively. Method: A double-blind, randomized, placebo-controlled trial comparing exposure and ritual prevention, clomipramine, their combination (exposure and ritual prevention plus clomipramine), and pill placebo was conducted at one center expert in pharmacotherapy, another with expertise in exposure and ritual prevention, and a third with expertise in both modalities. Participants were adult outpatients (N=122 entrants) with OCD. Interventions included intensive exposure and ritual prevention for 4 weeks, followed by eight weekly maintenance sessions, and/ or clomipramine administered for 12 weeks, with a maximum dose of 250 mg/ day. The main outcome measures were the Yale-Brown Obsessive Compulsive Scale total score and response rates determined by the Clinical Global Impression improvement scale. Results: At week 12, the effects of all active treatments were superior to placebo. The effect of exposure and ritual prevention did not differ from that of exposure and ritual prevention plus clomipramine, and both were superior to clomipramine only. Treated and completer response rates were, respectively, 62% and 86% for exposure and ritual prevention, 42% and 48% for clomipramine, 70% and 79% for exposure and ritual prevention plus clomipramine, and 8% and 10% for placebo. Conclusions: Clomipramine, exposure and ritual prevention, and their combination are all efficacious treatments for OCD. Intensive exposure and ritual prevention may be superior to clomipramine and, by implication, to monotherapy with the other SRIs.

(Reprinted with permission from the American Journal of Psychiatry 2005; 162:151–161)


Related Article:

Obsessive-Compulsive Disorder
John H. Greist and James W. Jefferson
Focus 2007 5: 283-298. [Abstract] [Full Text] [PDF]






Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org